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Abstract 
Background: Obesity, metabolic syndrome (MetS), and psoriasis, largely driven by environmental factors, show 
multiple bidirectional associations, with important metabolic implications in psoriatic patients. Besides body mass 
index (BMI) as a measure of obesity, data on phase angle (PhA), a direct measure by bioelectrical impedance analysis 
(BIA), used as a marker of cellular health and a predictor of morbidity and mortality in various diseases, are still lacking 
in psoriasis. In this case–control, cross-sectional study, we investigated the PhA in 180 pairs of adult psoriatic patients 
and healthy controls, evaluating also the potential use of the PhA as marker of the clinical severity, the quality of life, 
and the presence of the MetS in psoriatic patients.
Methods: Anthropometric measures, metabolic profile and bioelectrical variables were evaluated. The clinical sever-
ity was assessed by standardized psoriasis area and severity index (PASI) score and c-reactive protein (CRP) levels, and 
the quality of life was evaluated by dermatology life quality index (DLQI). MetS was diagnosed according to Adult 
Treatment Panel III.
Results: Psoriatic patients presented smaller PhA (p < 0.001) and higher prevalence MetS compared with controls. 
The PhA was significantly associated with number of parameters of MetS in both groups (p < 0.001). After adjusting 
for BMI, this association remained significant in psoriatic patients only (p < 0.001). Among psoriatic patients, the PhA 
was the major index value for the diagnosis of MetS (OR 5.87, 95 % CI 5.07–6.79) and was inversely associated with 
both PASI score and DLQI, independently of BMI (p < 0.001). At multiple regression analysis, the PhA well predicted 
the PASI score and DLQI. Based on ROC curves, the most sensitive and specific cutoffs of PhA to predict the highest 
PASI score and the lowest DQLI were ≤4.8° and ≤4.9°, respectively.
Conclusions: We reported that psoriatic patients presented small PhAs, with a novel association between PhA, clini-
cal severity, quality of life in psoriatic patients, and MetS. Further studies are required to validate the PhA’s prognostic 
ability in assessing the clinical severity and MetS in psoriatic patients.
Keywords: Environmental factors, Phase angle (PhA), Psoriasis area and severity index (PASI) score, Dermatology life 
quality index (DLQI), Metabolic syndrome (MetS)
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Among environmental factors, a growing body of evi-
dence supports the presence of multiple bidirectional 
associations among obesity, metabolic syndrome (MetS), 
and psoriasis, a chronic, immune mediated inflam-
matory skin disease with a complex component back-
ground [1, 2]. The precise mechanisms linking obesity, 
MetS, and psoriasis remain to be defined, but inflamma-
tory pathways mutual to both conditions are probably 
involved [3–6], with important metabolic implications 
in the prognosis of psoriatic patients [7]. In this con-
text, early detection and treatment of the metabolic 
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derangements associated to psoriasis might represent an 
important goal in the management of psoriatic patients 
[8]. In most of these studies, body mass index (BMI) has 
been employed as a measure of obesity. By contrast, only 
few studies have investigated the association between 
psoriasis and body composition [9]. In particular, rela-
tionships have been evidenced between body composi-
tion and the occurrence of psoriasis [10], the severity 
of the disease [11], or the response to treatment with 
anti-TNF-α agents [12]. Currently, measures of body 
composition are evaluated by bioelectrical impedance 
analysis (BIA). BIA is not however a direct method for 
assessment of body composition and its accuracy as an 
indicator of body composition could be hampered by 
an altered distribution of extra- and intra-cellular water 
(ECW and ICW) [13].
Differently from the other parameters obtained by 
BIA, the phase angle (PhA), a direct measure by BIA, is a 
rapid, easy and bloodless tool in clinical setting. The PhA 
represents either the reactance of tissues (Xc) associated 
with cellularity, cell size and integrity of the cell mem-
brane, and the resistance (R) of tissues, which is depend-
ent on lean tissue mass and tissue hydration [13–15]. It is 
well established that a decrease in PhA is consistent with 
cell death and reflects a breakdown of cell membranes, an 
expansion of the interstitial fluid space (volume) with a 
concomitant decrease in ICW resulting in an increased 
spacing among affected cells. On the other side, larger 
PhAs reflect higher quantities of intact cell membranes 
and lean body mass [16]. In healthy population, PhA is 
affected by a number of different factors, including age, 
sex, and BMI [17, 18]. In disease conditions, including 
MetS, PhA values are frequently lower than normal since 
either disease-specific parameters and disease-related 
inflammatory status may impair PhA [19]. In this regards, 
the use of the PhA has been recommended as a prognos-
tic marker of mortality in various chronic diseases [20], 
including cancer, and is associated with risk of morbid-
ity in diabetes [21] and obesity [22]. As long as we know, 
data on the risk of morbidity in psoriatic patients and the 
association between PhA and MetS the clinical setting of 
the chronic, systemic inflammatory status mutual to both 
conditions are still lacking.
Aim of this case–control, cross-sectional study was: (i) 
to investigate the differences in the PhA between patients 
affected with psoriasis and healthy controls; (ii) to evalu-
ate the association of the PhA with the clinical severity of 
the disease, assessed by standardized psoriasis area and 
severity index (PASI) score and c-reactive protein (CRP) 
levels, and the quality of life, evaluated by dermatology 
life quality index (DLQI); (iii) to verify the potential use-
fulness of PhA as an early marker of the MetS associated 
to psoriasis.
Methods
Design and setting
This is a case–control, cross-sectional observational 
study carried out at the Department of Clinical Medi-
cine and Surgery, Unit of Endocrinology, University 
Federico II, Naples (Italy). The work has been carried 
out in accordance with the Code of Ethics of the World 
Medical Association (Declaration of Helsinki) for experi-
ments involving humans, and it has been approved by 
the Ethical Committee of the University of Naples “Fed-
erico II” Medical School. The purpose of the protocol was 
explained to both the patients and the healthy controls, 
and written informed consent was obtained.
Population study
The study has been conducted on 180 adult patients out 
of 294 Caucasian subjects of both gender affected by pso-
riasis attending the Psoriasis Care Center of the Outpa-
tient Clinic of the Section of Dermatology, University of 
Naples Federico II from January 2014 to June 2015. In 
order to improve the power of the study, we increased 
the homogeneity of the patient sample by including 
adult treatment-naïve patients only, aged 18–65  years. 
The flow of study subjects is shown in Fig.  1. Patients 
were excluded from the study if they (1) had a diagnosis 
of psoriasis lasting >6 months or were receiving any sys-
temic treatment for psoriasis including acitretin, ciclo-
sporin, methotrexate, phototherapy or biologics for at 
least 3 months (21 patients); (2) had a diagnosis of pus-
tular (2 patients), erythrodermic (1 patient) or arthro-
pathic psoriasis (24 patients); (3) had skin damage on 
the area where the electrodes of the BIA were attached 
(8 patients); (4) had received any drug therapy known 
to affect water homeostasis (13 patients); (5) had a his-
tory of excessive alcohol use (11 patients); (6) were cur-
rent smokers (19 patients); (7) had neoplastic, metabolic, 
hepatic, and cardiovascular disorder or other concurrent 
medical illness (i.e., renal disease, and malabsorptive dis-
orders) (15 patients).
One hundred eighty non-psoriatic subjects were 
chosen as healthy controls among hospital volunteers 
and employees from the same geographical area. Con-
trols were matched on the basis of age, sex and BMI. 
The exclusion criteria for controls were the same as the 
patients, with the additional criterion that controls had 
no previous diagnosis of psoriasis.
The PASI score is the gold standard for the severity 
assessment and widely used tool for measuring psoriasis 
severity [23]. The scale evaluates four areas of the body 
(head/neck, upper limbs, trunk, and lower limbs) for ery-
thema, scaliness and thickness of psoriatic plaques. The 
PASI score can range from 0 to 72, with higher scores 
indicating greater severity. PASI score was used to be 
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recorded by measuring four body surface areas (head, 
chest, upper and lower limbs) with patient in a standing 
position according to the method described by Harari M 
et  al. 2000 [24] and the age at onset of it (early psoria-
sis: age <39 years and late psoriasis aged >40 years) were 
also noted. To prevent rate biases, the dermatologists 
who evaluated the PASI score were blinded to the design 
of the study. To assess the quality of life in our patients, 
we employed the dermatology life quality index (DLQI) 
[25]. The DLQI consists of ten questions organized in six 
sections. Those sections include symptoms and feelings 
(max. six points), daily activities (max. six points), leisure 
(max. six points), work and school (max. three points), 
personal relationships (max. six points) and treatment 
(max. three points). The achievable score ranges between 
0 and 30 points with higher scores indicating a greater 
impact on quality of life.
Anthropometric measurements
The measurements were made in a standard way by one 
operator (a nutritionist experienced in providing nutri-
tional assessment and body composition).
All anthropometric measurements were taken with 
subjects wearing only light clothes and without shoes. In 
each subject, weight and height were measured to calcu-
late the BMI [weight (kg) divided by height squared (m2), 
kg/m2]. Height was measured to the nearest 1 cm using a 
wall-mounted stadiometer. Body weight was determined 
to the nearest 50 g using a calibrated balance beam scale. 
Waist Circumference (WC) was measured to the closest 
0.1  cm with a non-extensible tape at the natural inden-
tation or at a midway level between the iliac crest and 
the lower edge of the rib cage if no natural indentation 
was visible. The measurement was made with the subject 
standing upright, feet together and arms hanging freely at 
the sides, with the subjects standing and breathing nor-
mally. The degree of obesity was established according 
to a scale based on BMI cut-off points: 35.0–39.9 (grade 
II obesity) and ≥40.0 kg/m2 (grade III obesity or severe 
obesity), respectively. Abdominal obesity was defined as: 
WC ≥102 cm in men and ≥88 cm in women. In all indi-
viduals were measured Systolic (SBP) and diastolic (DBP) 
blood pressure in three times, 2  min apart, with a ran-
dom zero sphygmomanometer (Gelman Hawksley Ltd., 
Sussex, UK) after the subject had been sitting for at least 
10 min. The average of the second and third reading was 
recorded.
Information on smoking habit, alcohol consump-
tion, and physical activity was obtained by a standard 
questionnaire. Current smokers were defined as those 
who smoked at least one cigarette per day and former 
smokers as those who had stopped smoking more than 
1  year before the interview; the rest of the participants 
were defined as noncurrent smokers. Participants were 
Fig. 1 Flow chart of study design
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also classified according to their alcohol intake into 
two groups: at least one glass of wine (or an equivalent 
amount of other alcoholic beverages per day) (YES) or 
no alcohol consumption (NO). Physical activity level was 
expressed according to whether the participant habitually 
engaged at least 30 min/day of aerobic exercise (Yes/No).
Metabolic syndrome and type 2 diabetes definitions
According to the NCEP ATP III definition, MetS is pre-
sent if three or more of the following five criteria are 
met: WC ≥102 cm (men) or 88 cm (women), blood pres-
sure ≥130/85 mmHg, fasting triglyceride level ≥150 mg/
dl, fasting high-density lipoprotein (HDL) cholesterol 
level ≤40 mg/dl (men) or ≤50 mg/dl (women), and fast-
ing glucose ≥100  mg/dl [26]. Type 2 diabetes (T2DM) 
was diagnosed according to ADA criteria [27].
Bioelectrical impedance analysis
Bioelectrical impedance analysis was performed using 
a BIA phase-sensitive system by experienced observ-
ers (single-frequency 50 kHz BIA 101 RJL, Akern Biore-
search, Firenze) [28]. Based on the European Society of 
Parenteral and Enteral Nutrition (ESPEN) guidelines [29], 
all participants were supine with limbs slightly spread 
apart from the body, refrained from eating, drinking, and 
exercising for 6 h and no alcohol within 24 h before test-
ing. Shoes and socks were removed and contact areas 
were scrubbed with alcohol immediately before electrode 
placement. Electrodes (BIATRODES Akern Srl; Florence, 
Italy) were placed proximal to the phalangeal–metacar-
pal joint on the dorsal surface of the right hand and dis-
tal to the transverse arch on the superior surface of the 
right foot. Sensor electrodes were placed at the midpoint 
between the distal prominence of the radius and ulna of 
the right wrist, and between the medial and lateral malle-
oli of the right ankle.
R (Ω, Ohm) and Xc (Ω, Ohm) were measured. The 
PhA was derived from conditions under 50 kHz accord-
ing to the following formula: PhA (◦, degrees) = 
arctangent Xc/R
((
Xc
/
R
)
×
(
180
/
pi
))
 .
Biochemical measurements
Samples were collected in study population between 
8 and 10 a.m. after an overnight fast of at least 8 h and 
stored at −80 °C until processed. All biochemical analy-
ses including glucose, total cholesterol, triglycerides, 
aspartate aminotransferase (AST), and alanine ami-
notransferase (ALT) were performed with a Roche 
Modular Analytics System in the Central Biochemistry 
Laboratory of our Institution. Low-density lipoprotein 
(LDL) and HDL cholesterol were determined by direct 
method (homogeneous enzymatic assay for the direct 
quantitative determination of LDL and HDL cholesterol). 
CRP levels were determined with a nephelometric assay 
with CardioPhase high-sensitive from Siemens Health-
care Diagnostics (Marburg, Germany). The intra-assay 
coefficients of variations (CV) for CRP was <4  %; low 
detection limit was >0.1 mg/l.
Statistical analysis
Results are expressed as mean ±  SD or as median plus 
range according to variable distributions evaluated by 
Kolmogorov–Smirnov test (p  <  0.01). To correct for 
skewed distributions, PASI score and DLQI were loga-
rithmically transformed and back-transformed for pres-
entation in text, tables and figures. Differences between 
psoriatic and healthy controls were analyzed by unpaired 
t test or Mann–Whitney U-test, as appropriate. The Chi 
square (χ2) test was used to determine the significance of 
differences in frequency distributions. The correlations 
between study variables were performed using Pearson 
r or Spearman’s rho correlation coefficients. Bivariate 
proportional odds ratio (OR) models were performed to 
assess the association among quantitative variables and 
qualitative variables (sex and presence/absence of MetS). 
Receiver operator characteristic (ROC) curve analysis 
was performed to determine sensitivity and specificity, 
area under the curve (AUC), and confidence intervals 
(CI), as well as cutoff values for PhA values in detecting 
the clinical severity and the quality of life of psoriatic 
patients. Test AUC for ROC analysis was performed. We 
want show that AUC resulted 0.957 for a particular test 
is significant from the null hypothesis value 0.5 (meaning 
no discriminating power), than we enter 0.957 for AUC 
ROC and 0.5 for null hypothesis values. For α level we 
selected 0.05 type I error and for β level we selected 0.20 
type II error. Two multiple regression analysis models 
(stepwise method), expressed as r2, Beta (β) and t, with 
PhA as dependent variables were used to estimate the 
predictive value of: (i) BMI, MetS parameters, and PASI 
score; (ii) BMI, MetS parameters, and DLQI. In these 
analyses, we entered only those variables that had a p 
value <0.05 in the univariate analysis (partial correlation). 
To avoid multicollinearity, variables with a variance infla-
tion factor (VIP) >10 were excluded. Values ≤5  % were 
considered statistically significant. Data were stored and 
analyzed using the MedCalc® package (Version 12.3.0 
1993- 2012 MedCalc Software bvba—MedCalc Software, 
Mariakerke, Belgium). Proportional odds model was car-
ried out using the R Project for Statistical Computing 
2014 (http://www.R-project.org).
Results
Study population consisted of 180 psoriatic patients, 
aged 21–65 years (71 % males), with BMI ranging 18.6–
53.4  kg/m2. Control group consisted of 180 subjects, 
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aged 29–65 years (71 % males), with BMI ranging 18.1–
49.7  kg/m2. Among psoriatic patients, PASI score was 
6.0 (0.20–28.80) and DLQI 1.3 (0.00–15.00). In psori-
atic patients and healthy group the prevalence of cur-
rent smoking was 36.7 vs 31.1 %, respectively (χ2 = 1.00; 
p = 0.316); the alcohol consumption was 28.9 vs 21.1 %, 
respectively (χ2 = 2.50; p = 0.114); while 33.3 vs 31.7 %, 
respectively (χ2  =  0.05; p  =  0.822) reported having 
practiced physical activity. Anthropometry, metabolic 
profile and bioelectrical variables of both groups were 
summarized in Table  1. In both groups the majority of 
participants were overweight/obese (77.8 and 69.4  %, 
respectively; χ2 = 2.80; p = 0.094). Psoriatic patients pre-
sented a worse metabolic profile, a higher prevalence of 
T2DM (22.8 vs 9.4 %, respectively; χ2 = 10.87; p = 0.001), 
lower Xc, smaller PhA, and higher CRP levels (p < 0.001) 
compared with non-psoriatic counterparts. As reported 
in Fig.  2, MetS was more frequently diagnosed among 
psoriatic patients than in healthy subjects. The PhA was 
evaluated according gender in both psoriatic and healthy 
subjects. In particular, gender-specific differences in the 
PhA between males and females were evidenced in both 
in healthy subjects and psoriatic patients (p  <  0.001 vs 
p = 0.008, respectively; Fig. 3a). However, compared with 
in healthy subjects, both males and females psoriatic 
patients had a smaller PhA (p < 0.001) (Fig. 3b).
Correlation studies
Correlations among PhA and study variables were 
analyzed in psoriatic patients and in healthy subjects 
separately, and reported in Table 2. The PhA showed sig-
nificant negative associations with almost all the meta-
bolic variables, although with some differences between 
the two groups. In particular, the PhA was significantly 
and negatively associated with age in healthy subjects 
only.
Among psoriatic patients, PASI score and DLQI evi-
denced also significant positive correlations with anthro-
pometric measures and metabolic profile, while between 
bioelectrical variables there were positive correlations 
with R and negative with Xc (Tables  3, 4). In addition, 
we found that PhA was significantly and negatively 
associated with either PASI score or DLQI (r = −0.810, 
p  <  0.001 and r = −0.424, p  <  0.001, respectively). The 
sample size used gives high power to test r (at p = 0.05 
and r = −0.827; power 99 %). These negative associations 
remained significant after correction for BMI (Fig.  4a) 
and DLQI (Fig. 4b).
In addition, the PhA was significantly and negatively 
associated with number of parameters of MetS and CRP 
levels, independently of BMI levels (p < 0.001) in psoriatic 
patients only. BMI, PhA, PASI score and DLQI bivariate 
proportional odds ratio models for presence/absence of 
MetS were reported in Table 5. Among psoriatic patients, 
a small PhA was significantly associated with high odds 
of MetS presence (OR 5.87, 95  % CI 5.07–6.79), with a 
smaller PhA influencing the presence of MetS. At model 
fittings, the PhA was the major index value for diagnosis 
of MetS compared with BMI, and with the measures of 
clinical severity and quality of life, also after adjustment 
for BMI.
Table 1 Descriptive and  comparative statistics: psoriatic 
patient versus control group
Psoriatic patients exhibited statistically significant differences compared with 
controls for anthropometric measurements, metabolic profile and bioelectrical 
variables. Results are expressed as mean ± SD or as median plus range 
according to variable distributions evaluated by Kolmogorov–Smirnov test. A 
p value in italic denotes a significant difference (p < 0.05). Differences between 
groups were analyzed by paired t test or Wilcoxon signed-rank test, when 
appropriate
BMI body mass index, WC waist circumference, SBP systolic blood pressure, 
DBP diastolic blood pressure, HDL high-density lipoprotein, LDL low-density 
lipoprotein, AST aspartate aminotransferase, ALT alanine aminotransferase, CRP 
c-reactive protein, R resistance, Xc reactance, PhA phase angle
Parameters Psoriatic patients
n = 180
Control group
n = 180
p values
Age (years) 50 (21.0–65.0) 48.0 (29.0–65.0) 0.623
Anthropometric variables
 Weight (kg) 85.7 ± 20.1 84.1 ± 21.7 0.447
 Height (m) 1.69 (1.49–1.92) 1.70 (1.50–1.85) 0.878
 BMI (kg/m2) 30.2 ± 6.1 29.6 ± 7.3 0.422
  Normal weight 
n (%)
40 (22.2 %) 55 (30.6 %) 0.094
  Overweight  
n (%)
55 (30.6 %) 47 (26.1 %) 0.413
  Obesity n (%) 85 (47.2 %) 78 (43.3 %) 0.525
 WC (cm) males 108.8 ± 17.0 96.3 ± 21.5 <0.001
 WC (cm) females 110.5 ± 26.3 95.2 ± 24.2 0.002
Metabolic profile
 SBP (mmHg) 130.0 (100.0–165.0) 125.0 (95.0–165.0) 0.010
 DBP (mmHg) 80.0 (50.0–100.0) 75.0 (50.0–100.0) 0.008
 Glucose (mg/dl) 105.0 (65.0–197.0) 96.0 (61.0–190.0) 0.026
 Total cholesterol 
(mg/dl)
197.5 (97.0–315.0) 171.0 (102.0–332.0) 0.025
 HDL cholesterol 
(mg/dl)
43.3 ± 11.0 45.7 ± 7.9 0.023
 LDL cholesterol 
(mg/dl)
132.6 ± 44.7 121.7 ± 51.8 0.049
 Triglycerides  
(mg/ml)
164.0 (36.0–402.0) 139.0 (66.0–273.0) 0.009
 AST (U/l) 28.0 (10.0–94.0) 27.0 (5.0–65.0) 0.013
 ALT (U/l) 29.0 (7.0–150.0) 25.0 (3.0–63.0) 0.022
 CRP levels (ng/ml) 3.1 (0.1–16.2) 1.1 (0.0–3.9) <0.001
Bioelectrical variables
 R (Ohm) 504.5 ± 85.8 492.9 ± 87.2 0.215
 Xc (Ohm) 45.4 ± 9.2 50.1 ± 10.4 <0.001
 PhA (°) 5.2 ± 1.0 5.8 ± 0.7 <0.001
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Fig. 2 Frequency of metabolic risk factors and MetS in psoriatic patients and control group. The psoriatic patients exhibited statistically significant 
differences compared with controls for all the parameters of the MetS. In particular: WC (72.8 vs 51.1 %; χ2 = 17.0, p < 0.001), SBP/DBP (44.4 vs 
31.1 %; χ2 = 6.3, p < 0.001), triglycerides (63.9 vs 22.8 %; χ2 = 60.3, p < 0.001), HDL-C (61.7 vs 30.6 %; χ2 = 33.8, p = 0.012); glucose (63.9 vs 47.8 %; 
χ2 = 8.8, p = 0.003) and MetS presence/absence (65.0 vs 31.7 %; χ2 = 38.7, p < 0.001); in psoriatic patients and control group, respectively. Accord-
ing to the NCEP ATP III definition, the MetS is defined as the coexistence of three or more of the following findings: (1) increased WC (≥102 cm for 
men and ≥88 cm for women), (2) hypertension (SBP/DBP ≥130/85 mmHg), (3) hypertriglyceridaemia (≥150 mg/dl), (4) low HDL cholesterol levels 
(≤40 mg/dl for men and ≤50 mg/dl for women) and (5) elevated fasting plasma glucose (≥100 mg/dl). Results are expressed as percentage. The 
Chi square (χ2) test was used to test the significance of differences between the two groups. A p value in bold type denotes a significant differ-
ence (p < 0.05). WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, MetS 
metabolic syndrome
Fig. 3 Difference in the PhA between psoriatic patients and control group according to gender. The gender-specific difference in the PhA between 
males and females was evidenced in psoriatic patients and control group (5.3 ± 1.0 vs 4.9 ± 0.9, p = 0.008 and 6.0 ± 0.7 vs 5.5 ± 0.7, p < 0.001; in 
males and females, respectively), (a) Although the PhA was smaller in males and females psoriatic patients than in controls, (5.3 ± 1.0 vs 6.0 ± 0.7, 
p < 0.001 and 4.9 ± 0.9 vs 5.5 ± 0.7, p < 0.001, respectively), (b). Results are expressed as mean ± SD according to variable distributions evaluated 
by Kolmogorov–Smirnov test. A p value in bold type denotes a significant difference (p < 0.05). Differences between groups were analyzed by 
paired t test
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At multiple regression analysis, among PASI score, 
BMI, and number of parameters of MetS (model 1) 
or DQLI (model 2), the PhA well predicted the sever-
ity of psoriasis expressed by PASI score; among DLQI, 
BMI, number of parameters of MetS (model 1) or DQLI 
(model 2), the PhA and MetS well predicted the quality of 
life measured by DLQI (Table 6).
ROC analysis for predictive values of the PhA in detect-
ing clinical severity of psoriasis (PASI) and quality of life 
(DQLI) was reported in Fig. 5a, b, respectively. From the 
AUC the number of cases required for each group was 
set at 11 (Fig. 5b). Based on ROC curves, the most sensi-
tive and specific cutoffs of the PhA to predict the highest 
PASI score and the lowest DQLI were ≤4.8° and ≤4.9°, 
respectively.
Discussion
The results of this case–control, cross-sectional study 
report a novel association between PhA, a general indi-
cator of cell membrane integrity, and psoriasis. In par-
ticular, our data well demonstrated that PhA was smaller 
in psoriatic patients than in healthy subjects, and that 
this difference is independently of gender. Moreover, 
the common association between PhA and age was not 
found in psoriatic patients. In addition, we found signifi-
cant correlations between PhA with the clinical severity 
of psoriasis, expressed by PASI score and CRP levels, 
and the quality of life in these patients, independently 
of BMI. Based on ROC curve analysis, PhAs  ≤  4.8° 
and ≤4.9° identified psoriatic patients who have the 
highest clinical severity and the lowest quality of life, 
respectively.
Our data confirms the association between PhA and 
MetS in healthy subjects [30, 31], while we are not aware 
of any previous study examining this association in pso-
riatic patients. As expected, in both groups smaller PhAs 
were correlated with a higher degree of MetS. This asso-
ciation was independent of BMI in psoriatic patients 
only, suggesting the major role of the chronic systemic 
inflammation of psoriasis on PhA.
The PhA is a derived measure obtained from the rela-
tion between the BIA direct measures of R and Xc [14]. 
Table 2 Correlations among the PhA and study variables in psoriatic patient and control group
Simple correlations and partial correlation adjusted for BMI among the PhA and anthropometric measurements, metabolic profile and bioelectrical variables. There 
was a significant negative association among the PhA and BMI, WC, lipid and hepatic profile, MetS and R and Xc; and significant positive association with HDL-
cholesterol. In addition, after adjusting for BMI, the associations among the PhA, metabolic parameters and CRP levels remained still significant in psoriatic patients 
only
Correlations among variables were analyzed using Pearson r or Spearman’s rho correlation coefficients. A p value in italic denotes a significant difference (p < 0.05)
PhA phase angle, BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein, LDL low-
density lipoprotein, AST aspartate aminotransferase, ALT alanine aminotransferase, MetS metabolic syndrome, CRP c-reactive protein, R resistance, Xc reactance
Parameters Psoriatic patients Control group
Simple correlation Adjusted for BMI Simple correlation Adjusted for BMI
r p value r p value r p value r p value
Age (years) −0.098 0.191 −0.101 0.189 −0.790 <0.001 −0.709 <0.001
Anthropometric variables
 BMI (kg/m2) −0.220 0.003 – – −0.551 <0.001 – –
 WC (cm) −0.273 <0.001 −0.155 0.045 −0.537 <0.001 −0.112 0.156
Metabolic profile
 SBP (mmHg) −0.119 0.112 −0.097 0.211 −0.259 <0.001 0.100 0.203
 DBP (mmHg) −0.125 0.094 −0.074 0.337 −0.311 <0.001 0.013 0.871
 Glucose (mg/dl) −0.027 0.721 0.001 0.990 −0.096 0.655 −0.049 0.539
 Total cholesterol (mg/dl) −0.261 <0.001 −0.331 <0.001 −0.332 <0.001 0.031 0.696
 HDL cholesterol (mg/dl) 0.286 <0.001 0.247 0.001 0.269 <0.001 0.045 0.570
 LDL cholesterol (mg/dl) −0.331 <0.001 −0.303 <0.001 −0.315 <0.001 0.015 0.853
 Triglycerides (mg/ml) −0.368 <0.001 −0.343 <0.001 −0.148 0.048 0.060 0.447
 AST (U/l) −0.200 0.007 −0.183 0.017 −0.248 0.041 0.014 0.855
 ALT (U/l) −0.235 0.001 −0.127 0.099 −0.261 <0.001 0.162 0.039
 MetS (n. parameters) −0.380 <0.001 −0.334 <0.001 −0.425 <0.001 −0.020 0.805
 CRP levels (ng/ml) −0.320 <0.001 −0.283 <0.001 −0.522 <0.001 0.036 0.647
Bioelectrical variables
 R (Ohm) −0.400 <0.001 −0.444 <0.001 −0.154 0.039 −0.069 0.385
 Xc (Ohm) 0.625 <0.001 0.579 <0.001 0.516 <0.001 0.449 <0.001
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R is the opposition offered by the body to the electrical 
flow, and it is inversely related to the water and electro-
lyte content of tissues. Xc is the opposition to the elec-
trical flow caused by the capacitance properties of the 
cell membrane, and variations can occur depending on 
its integrity, function, and composition [32]. The PhA 
is interpreted as an indicator of cellular health [18] and 
water distribution between the intra- and extracellular 
spaces [33]. Thus, the PhA is directly related to a low 
body cell mass [34] and to a high ECW/ICW ratio [35]. 
Different from the other parameters used to assess body 
composition measured by BIA, the PhA is considered to 
be valid also when the hydration status varies, as in obe-
sity and chronic inflammation [19, 20, 36]. Small PhA 
was reported in patients with cancer [20], diabetes [21], 
and obesity [22], possibly because of a reduction in the 
mass of metabolically active cells [37]. In addition, the 
adjunctive effect on cell damage of the inflammatory sta-
tus, commonly accompanying these conditions, should 
be considered [38].
Accordingly, the PhA has been proposed as a prog-
nostic indicator in cancer [20] and as index for assessing 
catabolic state in diabetic patients [21]. Buscemi et  al. 
[39] previously reported that a moderate osmotic effect 
of hyperglycaemia may induce a shift in ICW to ECW 
in diabetic patients, resulting in smaller PhA. This asso-
ciation has been recently confirmed by Dittmar et al. [21] 
who suggested the measurement of the PhA as independ-
ent prognostic markers of catabolic state and poor con-
trol in diabetic patients.
Table 3 Correlations among PASI score and study variable 
in psoriatic patients
Simple and partial correlation among PASI score, age, DLQI, anthropometric 
variables, metabolic profile and bioelectrical variables. There was a significant 
positive correlation among PASI score and DLQI, BMI, WC, SBP, DBP, glucose, 
lipid and hepatic profile, MetS and R; moreover there was a significant negative 
association with HDL-cholesterol and Xc. After adjustment for BMI, the 
association among PASI score and DBP, glucose, AST and ALT, were lost
Correlations among variables were analyzed using Pearson r or Spearman’s 
rho correlation coefficients. A p value in italic denotes a significant difference 
(p < 0.05)
PASI psoriasis area and severity index, DLQI dermatology life quality index, 
BMI body mass index, WC waist circumference, SBP systolic blood pressure, 
DBP diastolic blood pressure, HDL high-density lipoprotein, LDL low-density 
lipoprotein, AST aspartate aminotransferase, ALT alanine aminotransferase, MetS 
metabolic syndrome, CRP c-reactive protein, R resistance, Xc reactance
Parameters Simple correlation Adjusted for BMI
PASI score PASI score
r p value r p value
Age (years) 0.129 0.083 0.147 0.057
DLQI 0.632 <0.001 0.612 <0.001
Anthropometric variables
 BMI (kg/m2) 0.306 <0.001 – –
 WC (cm) 0.405 <0.001 0.272 <0.001
Metabolic profile
 SBP (mmHg) 0.219 0.003 0.162 0.036
 DBP (mmHg) 0.177 0.017 0.110 0.153
 Glucose (mg/dl) 0.181 0.015 0.109 0.158
 Total cholesterol (mg/dl) 0.398 <0.001 0.499 <0.001
 HDL cholesterol (mg/dl) −0.368 <0.001 −0.339 <0.001
 LDL cholesterol (mg/dl) 0.489 <0.001 0.462 <0.001
 Triglycerides (mg/ml) 0.503 <0.001 0.474 <0.001
 AST (U/l) 0.203 0.006 0.131 0.089
 ALT (U/l) 0.184 0.014 0.096 0.215
 MetS (n. parameters) 0.450 <0.001 0.362 <0.001
 CRP levels (ng/ml) 0.430 <0.001 0.383 <0.001
Bioelectrical variables
 R (Ohm/m) 0.312 <0.001 0.414 <0.001
 Xc (Ohm/m) −0.587 <0.001 −0.529 <0.001
Table 4 Correlations among  DLQI and  study variable 
in psoriatic patients
Simple and partial correlation among DLQI and age, anthropometric variables, 
metabolic profile and bioelectrical variables. There were significant positive 
correlations among BMI, WC, SBP, glucose, lipid profile and MetS; moreover 
there were significant negative associations with HDL-cholesterol and Xc. After 
adjustment for BMI, the association among DLQI and WC and glucose, were 
lost. Correlations among variables were analyzed using Pearson r or Spearman’s 
rho correlation coefficients. A p value in italic denotes a significant difference 
(p < 0.05)
DLQI dermatology life quality index, BMI body mass index, WC waist 
circumference, SBP systolic blood pressure, DBP diastolic blood pressure, 
HDL high-density lipoprotein, LDL low-density lipoprotein, AST aspartate 
aminotransferase, ALT alanine transaminase, MetS metabolic syndrome, CRP 
c-reactive protein, R resistance, Xc reactance
Parameters Simple correlation Adjusted for BMI
DLQI DLQI
r p value r p value
Age (years) 0.128 0.086 0.117 0.131
Anthropometric variables
 BMI (kg/m2) 0.254 0.001 – –
 WC (cm) 0.264 <0.001 0.087 0.258
Metabolic profile
 SBP (mmHg) 0.247 0.001 0.202 0.009
 DBP (mmHg) 0.136 0.069 0.094 0.224
 Glucose (mg/dl) 0.154 0.039 0.105 0.174
 Total cholesterol (mg/dl) 0.221 0.003 0.285 <0.001
 HDL cholesterol (mg/dl) −0.200 0.007 −0.155 0.044
 LDL cholesterol (mg/dl) 0.282 <0.001 0.245 0.001
 Triglycerides (mg/ml) 0.387 <0.001 0.301 <0.001
 AST (U/l) 0.106 0.156 −0.007 0.930
 ALT (U/l) 0.117 0.117 0.029 0.706
 MetS (n. parameters) 0.280 <0.001 0.186 0.016
 CRP levels (ng/ml) 0.357 <0.001 0.312 <0.001
Bioelectrical variables
 R (Ohm) 0.082 0.273 0.150 0.045
 Xc (Ohm) −0.404 <0.001 −0.336 <0.001
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In our study, as expected, psoriatic patients had a 
worse metabolic profile as compared with their matched 
counterparts, with a positive correlation between MetS 
parameters and the severity of psoriasis [40]. In addition, 
we found also a negative correlation between MetS and 
the quality of life in these patients. Of interest, PhA, a 
non-invasive and bloodless measure, was a major index 
value for the diagnosis of MetS in our group of psori-
atic patients. The identification of prognostic factors for 
psoriatic patients is important for the clinical manage-
ment of the disease, for facilitates the assessment of the 
severity and prognosis of the disease, and the adequate 
Fig. 4 Correlation among PASI score and DLQI with the PhA. There was a significant negative association among PASI score (a) and DLQI (b) with 
the PhA. Correlations among variables were analyzed using Pearson r correlation coefficient. PASI psoriasis area and severity index, DLQI dermatol-
ogy life quality index, PhA phase angle
Table 5 Bivariate proportional odds ratio models performed to  assess the association of  MetS (Yes/No) and  BMI, PhA, 
PASI score and DLQI in psoriatic patients
Bivariate proportional odds ratio models performed to assess the association of MetS (yes/no) and BMI (model 1), PhA (model 2), PASI score (model 3) and DLQI 
(model 4) in psoriatic patients. In model 2, the model fitting is better with presence of MetS than absence of MetS: small values of the PhA influence the presence of 
MetS among psoriatic patients. At model fittings, the PhA is a major index value for diagnosis of MetS. AIC value fitting and R2  are higher and lower, respectively, than 
the AIC value fitting and R2 of BMI, PASI score and DLQI. A p value in bold type denotes a significant difference (p < 0.05)
MetS metabolic syndrome, BMI body mass index, PhA phase angle, PASI psoriasis area and severity index, DLQI dermatology life quality index, AIC akaike information 
criterion, CI confidence interval
Odds p value 95 % CI
Model 1 BMI (kg/m2) <0.001
 MetS Yes 2.23 1.93–2.58
 MetS No 1.21 1.05–1.40
Adjusted for BMI
Model 2 PhA (°) <0.001
 MetS Yes 5.87 5.07–6.79
 MetS No 0.46 0.39–0.53
Model 3 PASI score <0.001
 MetS Yes 2.20 1.90–2.55
 MetS No 1.23 1.06–1.42
Model 4 DLQI <0.001
 MetS Yes 2.23 2.03–2.73
 MetS No 1.15 0.99–1.33
Model 1
BMI (kg/m2)
Model 2
PhA (°)
Model 3
PASI score
Model 4
DLQI
Model value fittings
 AIC 200.2 231.2 195.9 227.1
  R2 adj 0.06 0.01 0.17 0.04
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monitoring of its clinical progress. To the best of our 
knowledge, there are no previous studies evidencing the 
association of the PhA with the MetS, the clinical sever-
ity and the quality of life in adult obese patients with 
psoriasis.
Our findings indicated that, unlike the healthy subjects 
[14, 18], in our group of psoriatic patients there was no 
evidence of sex-related differences in the PhA, nor PhA 
was associated with age. In line with the phase angle ref-
erence values stratified by age, sex, and BMI [15], higher 
values of PhA are expected among men because the PhA 
increases together with the muscle mass and the body 
cell mass [13, 16, 32, 41]. Furthermore, the PhA tends to 
decrease with age, as a function of the reduction of mus-
cle mass and the influence of the alterations in the ICW/
ECW ratio associated with aging [14, 42]. In that, our 
data are not in line with the study of Stobäus et al. [19] 
showing a significant influence of age and sex on the PhA 
in a large series of hospitalized patients in a retrospective 
analysis. This apparent contrast let us to speculate that 
the generalized inflammatory milieu characterizing pso-
riasis could likely hamper the negative effects of aging on 
PhA in psoriatic patients.
The inflammatory milieu could also account for the 
association between PhA and quality of life in our group 
of psoriatic patients. Sarcopenia, an aging-induced gen-
eralized decrease in muscle mass, strength, and function 
[43], is related to poor quality of life [44, 45]. In general, 
studies on body composition in inflammatory disease 
have shown a premature and ‘accelerated’ development 
of sarcopenia, especially in those with higher activity 
of disease and disability [46]. Muscle loss, linked to the 
increased expression of tumor necrosis factor (TNF)-α, 
is commonly reported in psoriasis [12, 47]. Sarcopenia 
as well as obesity sarcopenia are associated with a small 
PhA [16, 48]. A small PhA was used as a measure of low 
lean body mass in children with bowel inflammatory dis-
eases [49]. Consequently, it is tempting to hypothesize 
Table 6 Multiple Regression analysis models (stepwise 
method) with the PhA as dependent variables to estimate 
the predictive value of: (i) BMI, MetS parameters, and PASI 
score; (ii) BMI, MetS parameters, and DLQI
Multiple linear regression analysis with the PhA as dependent variables were 
used to estimate the predictive value of PASI score BMI, MetS parameters and 
DLQI. In the model 1, the PhA was the major predictor of PASI score, while, in 
the model 2 DLQI and MetS parameters were the major predictor of the PhA. A p 
value in italic denotes a significant difference (p < 0.05)
PASI psoriasis area and severity index, BMI body mass index, MetS metabolic 
syndrome, DLQI dermatology life quality index, PhA phase angle
Multiple regression analysis
Parameters r2 β t p value
Model 1
 PASI score 0.670 −0.820 −19.10 <0.001
  Variables excluded
  BMI, MetS parameters
Model 2
 DLQI 0.204 −0.380 −5.70 <0.001
  MetS parameters 0.269 −0.274 −4.11 <0.001
  Variable excluded
  BMI
Fig. 5 Receiver operating characteristic analysis (ROC) for predictive values of the PhA in detecting clinical severity and quality of life. Based on ROC 
curves, the most sensitive and specific cutoffs of the PhA to predict the highest PASI score (a) and the lowest DQLI (b) were ≤4.8° and ≤4.9°, respec-
tively. PhA phase angle, PASI psoriasis area and severity index, DQLI dermatology life quality index, ROC receiver operating characteristic
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that PhA could be determined by the combined effects of 
either the low grade inflammation associated with MetS 
and the systemic inflammatory status associated with 
psoriasis on the muscle mass, which may go unrecog-
nized using BMI alone.
In summary, the major findings of this study were (i) 
psoriatic patients of both gender have smaller PhAs 
compared with healthy subjects, independently of age; 
(ii) PhA is independently and negatively associated 
with the clinical severity and the quality of life in psori-
atic patients; (iii) PhA is associated with MetS indepen-
dently of BMI, and represents a major index value for the 
diagnosis of MetS in psoriatic patients. Based on these 
findings, we hypothesize that the inflammatory milieu 
characterizing psoriasis could, on the one hand, account 
for the association of the PhA with MetS, the clinical 
severity, and the quality of life, independently of BMI 
and, on the other hamper the effect of age on the PhA.
Limitations of this study warrant some considerations. 
Firstly, the cross-sectional nature of this study did not 
allow to identify any causal association between psoriasis 
and PhA and to determine the prognostic value of PhA 
for predicting the MetS. Moreover, the suggested cut-off 
values of the PhA for diagnosing the clinical severity and 
the quality of life in our present study should be viewed 
with caution until results of studies in larger patient pop-
ulations have become available to perform an appropriate 
cross-validation. Second, the association between psoria-
sis and PhA should be verified considering also the dis-
ease duration, and the detection of circulating markers of 
inflammation different from PASI and CRP levels, such 
as pro-inflammatory cytokines. Finally, expert Nutri-
tionists are required for the assessment, execution and 
especially for interpretation of BIA measurements. How-
ever, this study has adequate statistical power and there 
were statistically significant differences in PhAs between 
psoriatic patients and healthy. In addition, in order to 
improve the power of the study, we applied very stringent 
inclusion criteria, such as a diagnosis of psoriasis lasting 
<6 months or the absence of any treatment for psoriasis.
Conclusions
Overall, the findings of this study suggest that the PhA, 
a simple biophysical parameter, could be incorporated 
into routine clinical practice, as index of clinical sever-
ity, quality of life the and MetS in psoriatic patients, and 
marker of lean mass deficits, which may go unrecognized 
using BMI alone. Further studies are required, with larger 
and more diversified samples with respect to the sever-
ity and the duration of disease, to enable a more accurate 
assessment of PhA’s prognostic ability in patients with 
psoriasis and to understand the potential mechanisms by 
which chronic inflammation affects both PhA and MetS.
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